Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel Targeted Oncology Days taking place virtually April 16 – 17, 2024.
波士頓，2024年4月10日（GLOBE NEWSWIRE）——康帕思治療公司（納斯達克股票代碼：CMPX）是一家臨床階段、專注於腫瘤學的生物製藥公司，開發用於治療多種人類疾病的專有抗體療法。該公司今天宣佈，該公司將參加2024年4月16日至17日虛擬舉行的Stifel靶向腫瘤學日。
Presentation details
Date: Tuesday, April 16
Time: 11 – 11:25 AM ET
Webcast Link:
演示詳情
日期：4月16日星期二
時間：美國東部時間上午 11 — 11:25
網絡直播鏈接：
Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass' Events page.
虛擬/重播可用性：公司演示將在Compass的活動頁面上存檔90天。
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass's pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. Compass was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics, Inc. website at .
關於康帕思療法
Compass Therapeutics, Inc. 是一家臨床階段、專注於腫瘤學的生物製藥公司，正在開發專有的基於抗體的療法，以治療多種人類疾病。Compass 的科學重點是血管生成、免疫系統和腫瘤生長之間的關係。Compass的新型候選產品線旨在靶向有效抗腫瘤反應所需的多種關鍵生物途徑。其中包括通過血管生成靶向藥物調節微血管，通過腫瘤微環境中效應細胞的激活劑誘導強效免疫反應，以及緩解腫瘤用來逃避免疫監測的免疫抑制機制。康帕思計劃通過臨床開發來推進其候選產品，既可以作爲獨立療法，也可以結合基於支持性臨床和非臨床數據的專有管道抗體。康帕思成立於2014年，總部位於馬薩諸塞州波士頓。欲了解更多信息，請訪問康帕思療法公司網站，網址爲。
Investor Contact
ir@compasstherapeutics.com
投資者聯繫人
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099
媒體聯繫人
安娜·吉福德，傳播經理
media@compasstherapeutics.com
617-500-8099
譯文內容由第三人軟體翻譯。